1 / 20

ADHD Drugs and Cardiovascular Outcomes Feasibility Study

Preliminary results of observational studies on ADHD drugs and cardiovascular outcomes feasibility, including design, drug exposure cohorts, study outcomes, power calculations, and proposal for echocardiographic study.

marius
Download Presentation

ADHD Drugs and Cardiovascular Outcomes Feasibility Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ADHD drugs and CV outcomes: Preliminary feasibility resultsand potential observational studies David J. Graham, MD, MPH on behalf of the FDA Epidemiology Contracts Study Team March 22, 2006

  2. FDA’s Epidemiology Contracts Program • Replaces Cooperative Agreement Program • Provides capability to study safety questions in a population setting • 4 awardees Covered lives • HMO Research Network 3.2 million • Ingenix (i3 Drug Safety) 12 million • Kaiser Permanente Research Institute 6.1 million • TN and WA Medicaid 2.2 million • Turnover: 1 yr: 8%-30%; 5 yrs: 25%-80% • Funding • 2005-06 $1.6 million • 2006-07 $0.9 million

  3. Feasibility study design • Inception cohorts, all ages • Study period • Jan 1998-June 2005 (i3, KPRI, Medicaid) • July 2000-June 2005 (HMO RN) • Drugs of interest • Amphetamine or dextroamphetamine • Methylphenidate • Atomoxetine • Age-groups • Children/adolescents (1-19 years) • Adults (20-64 years) • Outcomes of interest • Sudden unexplained death • Acute myocardial infarction • Other ischemic heart disease • Cerebrovascular accident • Arrhythmia • Hypertension • Pulmonary hypertension

  4. Details of ADHD drug exposure cohortsof children ≤ 19 years

  5. Persistency of ADHD drug use by drug in 0-19 year olds Methylphenidate Amphetamine Atomoxetine

  6. Background rates for cardiovascular events of interest in pediatric population age 1-19

  7. Counts of potential study outcomesin children age 1-19 years, based on hospital discharge diagnoses

  8. Deaths reported within pediatric ADHD-drug-exposed inception cohorts • Deaths occurred at any time after cohort entry • From any cause • In-hospital only from 2 sites, none from 1 site • Sudden out of hospital deaths included from 1 site • 2 sites have death certificate linkage; SCD validated at 1 • NDI search required with other 2 sites - turnover, time, $$

  9. Power to identify a given risk ratio with abackground rate = 15 per 105 person-years(AMI in children 1-19 years) RR=5 1.00 0.80 RR=3 0.60 Power (1-beta) RR=2 0.40 0.20 0.00 40 80 120 160 200 240 280 320 360 400 Exposure cohort person-years (thousands)

  10. Power to identify a given risk ratio with abackground rate = 3 per 105 person-years(CVA in children 1-19 years) 1.00 RR=10 0.80 RR=5 0.60 Power (1-beta) RR=3 0.40 0.20 RR=2 0.00 40 80 120 160 200 240 280 320 360 400 Exposure cohort person-years (thousands)

  11. Event number and statistical power required to confirm risk ratios from 2 to 10 RR=2 RR=3 RR=5 RR=10

  12. Probability of excluding a given risk ratio, assuming true RR=1: background = 15 per 105 person-years(AMI in children age 1-19) RR=5 RR=3 RR=2

  13. Probability of excluding a given risk ratio, assumingtrue RR=1: background = 3 per 105 person-years(CVA in children age 1-19) RR=10 RR=5 RR=3 RR=2

  14. Estimated risk ratio that can be detected with  80% probability by age- and drug-group

  15. Some additional power considerations AMI: acute myocardial infarction CVA: cerebrovascular accident (stroke)

  16. Caveats regarding ADHD cohort study • Preliminary data; relationship of drug exposures to outcomes not yet studied • Crude definitions of exposure, outcome • Hospital D/C diagnoses, not validated • Outcome post 1st Rx; timing with current use not known • Out of hospital deaths (SCD) not captured at 2 sites • Power calculations crude • Uncertainty regarding background rates (i.e., AMI)

  17. Proposal offered at February advisory meeting • Observational echocardiographic study • Within a large healthcare database: • Identify patients treated with ADHD drugs for varying durations of time • Select suitable untreated “controls” from same population • Perform echocardiography and assess • Left ventricular wall thickness • Contractility

  18. Patient sampling for echocardiographic study Methylphenidate Amphetamine Atomoxetine

  19. Summary • Concern regarding potential for CV risk of ADHD drugs • High prevalence of use in children; growing in adults • Sudden unexplained death of 1 interest; most difficult to study • TN Medicaid and KPRI have death certificate linkage • Other sites would require NDI search • Other CV outcomes • Feasibility study • Exposed person-time substantial for most ADHD drugs • CV outcomes require validation; timing with respect to exposure • Statistical power and uncertainty • Number of arrhythmia cases seems surprisingly high • Now in process of obtaining cost estimates for in-depth study

  20. FDA Epidemiology Contracts ADHD Study Team (list by site) • FDA, ODS • Andrew Mosholder, MD, MPH • Kate Gelperin, MD, MPH • Judy A. Staffa, PhD • David J. Graham, MD, MPH • HMO Research Network • Susan E. Andrade, PhD • Ingenix (i3 Drug Safety) • K. Arnold Chan, MD, ScD • Kaiser Permanente Research Institute • Joe Selby, MD, MPH • Medicaid (TN and WA) • William Cooper, MD, MPH

More Related